Live webinar took place April 9th, 2020
Demonstrating monoclonality and maintaining cell viability in cell line development are prerequisites for efficient development of cell lines for producing therapeutic proteins. The first part of this session focusses on CYTENA´s single-cell dispensing technology and on setting up an automated and efficient CLD workflow for generation of high-quality clones.
In the second part of the session we will introduce the c.bird, a new 96-well microbioreactor for early suspension culture. We will discuss how the c.bird results in higher cell densities and increased protein yield early in the cell line development process, and ultimately, saves time and cost.
In 2020, the majority of top pharma companies used CYTENA’s single-cell dispensing technology to ensure fast antibody development.
